EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune-Checkpoint Expression in Breast Cancer Patients: Clinicopathological Implications: A Retrospective Case Series Study

Angel Quiroz-Bolaños, Antonio Quintero-Ramos iD, Juliana Marisol Godínez-Rubí iD, Ramon Franco-Topete iD, Porfirio Gutiérrez González, Bricia M Gutiérrez-Zepeda iD, Denisse S Becerra-Loaiza iD, Antonio Topete, Cesar de Loera-Rodriguez, Alicia Del Toro-Arreola, Adrián Daneri-Navarro iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26125851 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Angel Quiroz-Bolaños und 10 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 950 Sierra Mojada St., Independencia, Guadalaja…. Hauptthemen laut MEDLINE: Breast Neoplasms, Immune Checkpoint Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejo Estatal de Ciencia y Tecnología, COECYTJAL.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy with antibodies targeting immune checkpoints, in combination with standard therapies, is one of the areas with the most significant clinical research, particularly in aggressive tumors such as triple-negative breast cancer, where there have been relevant advances with antibodies against PD-1/PD-L1. However, it is essential to define the biological and molecular factors that influence survival and response to immunotherapy, as other immune control points, such as CTLA-4, TIM-3, LAG-3, TIGIT, and VISTA, also play a role. The immune checkpoints were studied by microarrays and immunohistochemistry in 243 samples from patients with breast cancer, according to the molecular subtype. Significant differences in PD-1, PL-1, CTLA-4, and TIGIT expression were observed between triple-negative and Her-2 tumors compared to Luminal A and Luminal B tumors. No differences in VISTA expression were observed between the different molecular subtypes. Patients with high-grade tumors showed higher PD-1, PD-L1, LAG-3, and VISTA expression than low and intermediate-grade tumors. We observed a significant difference in PD-L1/TIGIT co-expression in tumor-infiltrating cells from patients with triple-negative tumors compared to patients with Luminal A, Luminal B, and Her2+ tumors. These results are relevant in the context of clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsImmune Checkpoint ProteinsHumansFemaleMiddle AgedRetrospective StudiesAdultAgedLymphocyte Activation Gene 3 ProteinBiomarkers, TumorB7-H1 AntigenProgrammed Cell Death 1 ReceptorTriple Negative Breast NeoplasmsReceptors, ImmunologicErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

immune-checkpoint expressionoverall survivaltriple-negative breast cancer

Substanzen

Lymphocyte Activation Gene 3 ProteinImmune Checkpoint ProteinsBiomarkers, TumorB7-H1 AntigenProgrammed Cell Death 1 ReceptorReceptors, ImmunologicErb-b2 Receptor Tyrosine KinasesLag3 protein, humanCD274 protein, humanTIGIT protein, human

Autor:innen und Institutionen

  • Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 950 Sierra Mojada St., Independencia, Guadalajara 44340, Jalisco, Mexico.
  • Departamento de Microbiología y Patología, Laboratorio de Patología Diagnóstica e Inmunohistoquímica (LAPADI), Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 950 Sierra Mojada St., Independenc…
  • Departamento de Matemáticas, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.
  • Doctorado en Genética Humana, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.
  • Departamento de Aparatos y Sistemas II, Facultad de Medicina, Decanato Ciencias de Salud, Universidad Autónoma de Guadalajara, Zapopan 45129, Jalisco, Mexico.
  • Colloids and Polymers Physics Group, Particle Physics Department, Institute of Materials (iMATUS), and Health Research Institute (IDIS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.

ORCID-Profile: Antonio Quintero-Ramos, Juliana Marisol Godínez-Rubí, Ramon Franco-Topete, Bricia M Gutiérrez-Zepeda, Denisse S Becerra-Loaiza, Adrián Daneri-Navarro

Förderung

  • Consejo Estatal de Ciencia y Tecnología
  • COECYTJAL

Zitieren

APA

Quiroz-Bolaños, A., Quintero-Ramos, A., Godínez-Rubí, J. M., Franco-Topete, R., González, P. G., Gutiérrez-Zepeda, B. M., Becerra-Loaiza, D. S., Topete, A., de Loera-Rodriguez, C., Toro-Arreola, A. D., & Daneri-Navarro, A. (2025). Immune-Checkpoint Expression in Breast Cancer Patients: Clinicopathological Implications: A Retrospective Case Series Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125851

Vancouver

Quiroz-Bolaños A, Quintero-Ramos A, Godínez-Rubí JM, Franco-Topete R, González PG, Gutiérrez-Zepeda BM, et al. Immune-Checkpoint Expression in Breast Cancer Patients: Clinicopathological Implications: A Retrospective Case Series Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125851

BibTeX
@article{QuirozBolaos2025,
  author = {Quiroz-Bolaños, Angel and Quintero-Ramos, Antonio and Godínez-Rubí, Juliana Marisol and Franco-Topete, Ramon and González, Porfirio Gutiérrez and Gutiérrez-Zepeda, Bricia M and Becerra-Loaiza, Denisse S and Topete, Antonio and de Loera-Rodriguez, Cesar and Toro-Arreola, Alicia Del and Daneri-Navarro, Adrián},
  title = {Immune-Checkpoint Expression in Breast Cancer Patients: Clinicopathological Implications: A Retrospective Case Series Study},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26125851}
}
Kostenlos starten →